Drug intelligence / Profile preview

shenqigui

Development stage: Preclinical
Lead developer: Chengdu First Pharmaceutical
Administration: Oral

Overview

Shenqigui is an oral liquid that is being investigated for its potential to improve bone marrow suppression in patients with small cell lung cancer who are undergoing chemotherapy. Specifically, it targets patients diagnosed with a Qi and yin deficiency type. This traditional Chinese medicine-based intervention is developed by Chengdu First Pharmaceutical Co. LTD and Chengdu University of Traditional Chinese Medicine and is administered orally.

Brand names: Shen-Qi-Gui
Other names: Shenqigui oral liquid肾气归口服液

Targets

JUN (Transcription factor Jun)JNK (Mitogen-activated protein kinase kinase kinase family)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)MYC (MYC proto-oncogene protein)

Beyond the preview

Go deeper on shenqigui.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shenqigui.

Explore the full profile